Open access peer-reviewed chapter

Aldosterone Synthase Gene (CYP11B2) Polymorphisms and Enhanced Cardiovascular Risk

Written By

Muhammad Tarek Abdel Ghafar

Submitted: March 15th, 2019 Reviewed: August 12th, 2019 Published: October 9th, 2019

DOI: 10.5772/intechopen.89133

Chapter metrics overview

903 Chapter Downloads

View Full Metrics


Aldosterone, the principal human mineralocorticoid, acts mainly for sodium reabsorption with potassium and hydrogen excretion. The adrenal cortex is the main site of aldosterone synthesis; however, extra-adrenal tissues such as the nervous, the cardiovascular, and the adipose tissues may be involved. Therefore, its action is mediated via endocrine as well as paracrine or autocrine mode. Aldosterone receptors are distributed extensively in the renal distal nephron and other sites, such as the heart, brain, vessels, and liver. The aldosterone synthase catalyzes the conversion of deoxycorticosterone finally to aldosterone. CYP11B2 gene occupies human chromosome 8q21-22 with nine exons and eight introns. Alteration of aldosterone synthase gene that is attributable to genetic polymorphisms can affect its transcription leading to several cardiovascular disorders such as essential hypertension, myocardial infarction, cardiomyopathies, and atrial fibrillations. Accordingly, it is important to illustrate these polymorphisms and the mechanisms by which they alter the aldosterone synthase gene and produce cardiovascular dysfunctions.


  • aldosterone
  • CYP11B2
  • polymorphisms
  • risk
  • transcription

1. Introduction

CYP11B2enzyme is one of the enzymes in the pathway of steroidogenesis and responsible for the catalysis of the last three steps in the aldosterone biosynthetic cascade. It is encoded by CYP11B2gene located on human chromosome 8q21-22. The genetic element of cardiovascular disorders has been emerged as a risk factor for the progression of these disorders. Among these genetic elements, CYP11B2genetic variants and haplotypes play a pivotal role in the susceptibility, progression, survival, and therapeutic response of many cardiovascular disorders such as hypertension, coronary heart disease (CAD), atrial fibrillation (AF), cardiomyopathy, heart failure (HF), and other disorders. It was suggested to influence the cardiovascular system via alteration of aldosterone production, which acts either directly on the heart or systemically via stimulating sodium and water reabsorption and increasing the blood pressure.


2. Aldosterone

2.1 Aldosterone biosynthesis

Aldosterone is the main human mineralocorticoid. The main site of aldosterone synthesis is the zona glomerulosa (ZG) in the adrenal cortex. However, it can be produced by extra-adrenal tissues such as the central nervous system, the cardiovascular system, and the adipose tissue with a non-detectable physiological relevance and a small contribution to circulating aldosterone levels [1].

It is synthesized from cholesterol by a group of enzymatic cascade (Figure 1). First, cholesterol is translocated into the mitochondria across its wall mediated by steroidogenic acute regulatory protein (StAR). Cholesterol is then converted to pregnenolone, through three reactions, a 20α-hydroxylation, a 22-hydroxylation, and cleavage of the bond between C-20 and C-22 catalyzed by the CYP11A1cleavage enzyme, encoded by the CYP11A1gene on human chromosome 15 [2].

Figure 1.

Enzymatic cascade of the aldosterone biosynthesis.

The produced pregnenolone is then released into the cytoplasm where it undergoes dehydrogenation of the 3β-hydroxyl group and isomerization of the double bond at C-5 to Δ4 by 3β-hydroxysteroid dehydrogenase (3β-HSD) and converted to progesterone [3]. Furthermore, progesterone undergoes 21-hydroxylation by the CYP21Aenzyme encoded by CYP21Amapped to human chromosome 6p21·3 and located on the cytoplasmic surface of the smooth endoplasmic reticulum, generating 11-deoxycorticosterone (DOC). Then, DOC passes through three consecutive reactions catalyzed by aldosterone synthase enzyme, located on the inner mitochondrial membrane and encoded by the CYP11B2gene, 11β-hydroxylation to corticosterone, 18-hydroxylation to 18-hydroxycorticosterone, and finally 18-methyloxidation to aldosterone [4].

2.2 Mechanism of action of aldosterone

The action of aldosterone is mediated though mineralocorticoid receptor (MR), a specific nuclear receptor that comprises N-terminal domain, DNA-binding domain, and C-terminal ligand-binding domain. It is present as a hetero-oligomeric complex with heat-shock proteins in the cell. Once aldosterone binds to its receptor, it undergoes a conformational change resulting in dissociation of the associated proteins, dimerization, and nuclear translocation [5]. This hormone receptor complex combines with the steroid responsive elements in the 5′-UTR of aldosterone-responsive genes with the release of aldosterone-induced proteins (AIP) that enhances or suppresses gene transcription [4].

The serine threonine glucocorticoid regulated kinase 1 (sgk1), which is one of the AIP proteins, has been phosphorylated and activated by the aldosterone, which in turn phosphorylates epithelial sodium channel (ENaC) regulatory protein, known as Nedd4–2, reducing its binding to ENaC [6] with subsequent increase in ENaC density and stability at the apical membrane resulting in increased ENaC-dependent Na+ reabsorption [7]. The glucocorticoid-induced leucine zipper (GILZ) and the corticosteroid hormone-induced factor (CHIF) are also AIP proteins. GILZ interacts with aldosterone inhibiting the ERK signaling pathway, thus liberating ENaC from Nedd4 proteins; accordingly, its action in blocking sodium reabsorption is inhibited [8]. CHIF may affect the baso-lateral Na/K-pump, resulting in increased sodium reabsorption with potassium or hydrogen ion excretion (Figure 2) [9]. Aldosterone also exerts a genomic action via modulating the gene expression and subsequent protein production that result in a lag time of 1–2 h before a noticeable change in target cell activity occur [10].

Figure 2.

Mechanism of action of aldosterone in epithelial cells. Abbreviations: ENaC, epithelial sodium channel; HRE, hormone response element; GILZ, glucocorticoid-induced leucine zipper protein; Nedd4-2, neuronal precursor cell-expressed, developmentally down-regulated protein; Sgk1, serine threonine glucocorticoid regulated kinase 1; CHIF, channel-inducing factor; MR, mineralocorticoid receptor.

2.3 Physiological action of aldosterone

As the kidneys are the main site of action for aldosterone, MRs are confined mainly in high concentration to the renal distal convoluted tubules and collecting duct controlling the apically located epithelial sodium channels at their luminal cells. Mineralocorticoid receptors also exist in other epithelial sites, such as the colon, sweat gland ducts, salivary glands [11], and non-epithelial sites including myocytes, endocardium of the heart, brain, vascular smooth muscle, liver, and leukocytes [12]. The main action of aldosterone is stimulation of sodium reabsorption in the kidney and at other secretory epithelial sites with excretion of potassium and hydrogen ions [13] possibly mediated via increasing the opening periods of the existing ion channels or increasing their number [14].

In cardiovascular system, aldosterone promotes myocardial hypertrophy and fibrosis via increasing collagen I synthesis in cardiac fibroblasts and also elevating endothelin receptor numbers that further increases collagen synthesis [15]. So, increased expression of mineralocorticoid receptors in the heart may result in left-ventricular hypertrophy in normotensive subjects [16]. Aldosterone also stimulates vascular constriction via enhancing the pressor response to catecholamines and impairing the vasodilatory response to acetylcholine or by upregulation of angiotensin II receptors [4]. Also, aldosterone excess can trigger collagen deposition in blood vessels, enhancing vascular remodeling and reducing compliance [17]. In the CNS, it appears to regulate blood pressure, salt appetite, and sympathetic tone [4].

Under normal circumstances, it is likely that cardiac MRs are occupied by glucocorticoid due to its higher circulating concentration exerting antagonistic effect attenuating the rise in blood pressure and the cardiac fibrosis caused by aldosterone alone [18].


3. Cytochrome P450 11B2 (CYP11B2)

3.1 Reaction catalyzed

CYP11B2enzyme is located in the inner mitochondrial membrane. Aldosterone synthesis from 11-deoxycorticosterone is catalyzed by CYP11B2enzyme, more commonly referred to as aldosterone synthase, which catalyzes three sequential reactions, each utilizing one molecule of NADPH, one molecule of oxygen, and the mitochondrial electron transfer system. The three sequential reactions are as follows: the 11β-hydroxylation of 11 deoxycorticosterone, the hydroxylation of carbon 18, followed by oxidation of the carbon 18 hydroxyl group to yield the carbon 18 aldehyde group resulting in the formation of aldosterone (Figure 3) [19].

Figure 3.

Enzymatic reactions catalyzed byCYP11B2enzyme.

3.2 Molecular structure

CYP11B2gene is located on human chromosome 8q21-22. It consists of nine exons, eight introns, and comprises about 7 kb (Figure 4). Its coding region is 95% identical, and its intronic region is 90% identical with CYP11B1. However, its 5′ untranslated region is different from that of CYP11B1gene, thus accounting for the differences in regulation and expression pattern for each gene [20].

Figure 4.

Schematic diagram of the exonic-intronic arrangement of theCYP11B2genes.

3.3 Protein structure

The human CYP11B2proteins are located in the inner mitochondrial membrane and consist of 503 amino acids, including a 24-residue N-terminal mitochondrial targeting sequence. At the protein level, the enzyme is 93% homologous with CYP11B1reflecting its shared 11β-hydroxylase and 18-hydroxylation activity. Only 37 amino acids differ between them which accounts for their different functions. Although CYP11B1and B2consist of the same number of amino acid, the apparent molecular mass of the human enzymes was reported as 51 and 49 kDa, respectively [20].

3.4 Tissue-specific expression

Expression of CYP11B2is limited to the adrenal cortex and appears to be exclusively in adrenal zona glomerulosa cells [21].

3.5 Regulation of CYP11B2expression

Adrenal steroidogenesis is under both acute and chronic regulation by tropic hormones. The acute response occurs within minutes and involves the mobilization of cholesterol from intracellular stores to the mitochondrial membrane in response to ACTH, angiotensin II, K+, and their respective intracellular messenger pathways. The chronic response takes several hours and involves the transcription of the genes encoding the steroidogenic enzymes [22].

3.5.1 Signaling pathways that regulate aldosterone production ACTH

Adrenocorticotrophin (ACTH) is a 39 amino acid peptide released from the anterior pituitary in pulsatile and diurnal rhythm with the highest levels in the morning and the lowest at night [23]. ACTH exerts its effects by binding to its receptor (ACTH-R), a G-protein-coupled receptor. ACTH acutely stimulates aldosterone secretion but in the long term has an inhibitory effect on CYP11B2gene expression and aldosterone levels [24].

Acute stimulation of aldosterone production has suggested to be mediated via activation of StAR protein production. Also, ACTH after binding to its receptor can activate adenylate cyclase, resulting in an increased intracellular cAMP concentration, activation of protein kinase A (PKA), and calcium influx via calcium channels (Figure 5) [25].

Figure 5.

Intracellular mechanisms of angiotensin II, K+ and ACTH influencing gene expression. Abbreviations: ER, endoplasmic reticulum; AT1-R, angiotensin 1 receptor; PLC, phospholipase C; PKA, protein kinase A; IP3R, inositol triphosphate receptor; IP3, inositol triphosphate; CaMK, calmodulin kinase; SF-1, steroidogenic factor 1; CREB, cAMP regulatory element response element; ACTH, adrenocorticotrophic hormone.

On the other hand, chronic ACTH stimulation may depress serum aldosterone level as cyclic AMP, the second messenger for ACTH, desensitizes adrenocortical cells to angiotensin II by causing a reduction in the expression of angiotensin II receptors. ACTH may also decrease aldosterone production by stimulating the expression of CYP11B1and CYP17, thereby resulting in a removal of precursors from the aldosterone pathway and using them to synthesize cortisol. ACTH appears to specifically induce the proliferation of zona fasciculata cells while recruiting and transforming glomerulosa cells into fasciculata-like cells [26].

Under normal circulating ACTH levels, the glomerulosa maintains CYP11B2expression by at least two mechanisms. First, angiotensin II inhibits ACTH-stimulated cAMP production in glomerulosa but not fasciculata cells. Second, the glomerulosa expresses a type of adenyl cyclase that is inhibited by increasing intracellular Ca2+, the second messenger for both angiotensin II and K+ [27]. Angiotensin II

Angiotensin II is thought to stimulate aldosterone synthesis as result of sodium depletion and extracellular fluid volume reduction through various intracellular signaling pathways. However, the best characterized pathway is the activation of phospholipase C (Figure 5). It is mediated by acting on angiotensin 1 (AT1) receptor, a specific G-protein-coupled receptor that activates phospholipase C. Once activated, phospholipase C hydrolyses phosphatidyl inositol 4,5-biphosphate (PIP2) to 1,4,5 inositol triphosphate (IP3) and 1,2-diacylglycerol (DAG) resulting in release of Ca2+ from intracellular stores and activation of protein kinase C (PKC), respectively. The increased intracellular Ca2+ concentration activates calmodulin and Ca2+/calmodulin-dependent protein kinases (CaM kinases) [28, 29] to phosphorylate and activate transcription factors as activating transcription factor 1 (ATF-1), cAMP-response-element binding protein (CREB), nerve growth factor IB (NGFIB), and nuclear receptor related 1 protein (NURR1) that combined to specific cis-acting series in the 5′ region of CYP11B2[30]. The acute stimulation mediated by angiotensin II can stimulate rapid aldosterone synthesis either de novo or from intermediate compounds in the steroidogenic pathway. However, chronic stimulation may lead to ZG hypertrophy and hyperplasia with increased CYP11B2expression and subsequent aldosterone secretion [31]. Potassium

The level of potassium affects renin secretion as well as having a direct effect on the adrenal cortex to increase aldosterone secretion. Increased extracellular K+ (like angiotensin II) stimulates aldosterone secretion through an increase in intracellular Ca2+ and activation of calmodulin kinases with consequent phosphorylation of transcription factors leading to stimulation of CYP11B2gene transcription. Potassium signaling is mediated through membrane depolarization, leading to an influx of calcium through T and L-type channels (Figure 5) [32].

3.5.2 Transcriptional regulation of CYP11B2gene

As mentioned previously, chronic regulation of steroidogenesis involves transcription of the genes encoding the necessary steroidogenic enzymes. This is mediated by alteration of trans-acting factors that bind to the cis-regulatory elements within the 5′ regulatory regions of the target genes. Investigation of the 5′ regulatory regions of the CYP11Bgene revealed six cis-acting elements (Ad1–6) (Figure 6). The most important cis-elements in the hCYP11B2promoter are CRE at −71/−64 (Ad1), Ad5 at −129/−114, Ad4 at −344/−336, and a cis-element termed NGFIB response element 1 (NBRE-1) −766/−759 (Figure 7) [33].

Figure 6.

Schematic diagram of theCYP11B2promoter with the cis-elements (Ad1–Ad6).

Figure 7.

Schematic diagram of the most important transcription factor binding sites in thehCYP11B25’UTR. Abbreviations: CREB, cAMP regulatory element response element; SF-1, steroidogenic factor 1; COUP-TF, chicken ovalbumin upstream promoter transcription factor; NGFIB, nerve growth factor IB; NURRI, nuclear receptor-related 1 protein; NBRE-1, NGFI-B response element. Ad1 (CRE)

The Ad1 element closely resembles a consensus cAMP regulatory element (CRE) site. CREs plays an essential role in cAMP-dependent gene expression of a wide variety of genes. Proteins, such as the CRE-binding protein (CREB) and the highly related activating transcription factors (ATF), bind to CRE sites to initiate transcription. CREB binds to DNA as a dimer and has a conserved region of leucine residues (leucine zipper) at its C terminus that enables dimerization and sequence specific DNA binding [34].

CREB functions not only as a component of a variety of signaling pathways, particularly PKA, but also mitogen-activated protein kinases (MAPKs) and CaMKs. All these pathways mediate CREB-induced transcription by phosphorylating CREB at residue serine 133 [35]. The phosphorylated serine 133 binds another protein referred to as the CREB-binding protein (CBP). CBP is a 265-kDa nuclear protein, which binds to phosphorylated CREB and allows recruitment and stabilization of the RNA polymerase II transcription complex on the promoter of CREB target genes [36].

Using electrophoretic mobility shift assay, the CYP11B2CRE has been shown to bind members of the activating transcription factor (ATF-1 and ATF-2) and CRE-binding protein (CREB) families. The ability of these transcription factors, particularly ATF-1 and CREB, to enhance transcription is partially regulated by their state of phosphorylation. Thus, one possibility is that activated CaMK I or CaMK IV phosphorylates CREB or ATF-1 leading to increased CYP11B2transcription [28]. AD4 (SF-1)

The Ad4 site (CCAAGGTC) is also found to be important in the regulation of the CYP11Bgene. This Ad4 site or homologous sequences have been identified in the regulatory regions of all other steroid P450 genes (CYP11A1, CYP21, CYPI7, CYP11B1, CYP11B2, and CYPI9), suggesting an important functional role in steroidogenesis. An Ad4-binding protein (Ad4BP) has been identified and cloned from bovine adrenal cortex nuclear extract. Ad4BP is a homolog of the steroidogenic factor 1 (SF-1) identified in the human [37].

SF-1 is an orphan member of the nuclear hormone receptor superfamily, with potential phosphorylation sites for cAMP-dependent kinases, CaMK or PKC, suggesting a role for SF-1 in cAMP-dependent transcription. SF-1 is a 53 kDa protein consisting of a zinc finger domain and ligand binding/dimerization domain. The hydroxyl cholesterols enhance SF-1-dependent transcriptional activity in vitro, suggesting that SF-1 is a ligand-activated receptor. However, this is a controversial finding and needs further clarification [38].

SF-1 is expressed exclusively in steroidogenic tissues and plays an essential role in the development and function of the primary steroidogenic tissues [39]. Within the adrenal, SF-1 has been found to play a key role in the transcriptional regulation of most of the steroid hydroxylase genes (CYP11A1, CYP21, CYP11B1, CYP17, and CYP 19) as well as three β HSDand steroidogenic acute regulatory protein(StAR). SF-1 regulation of transcription is mediated by interaction with various co-activator proteins, including steroid receptor coactivator 1 (SRC1), glucocorticoid receptor interacting protein (GRIP), and also through repressors such as dosage-sensitive adrenal hypoplasia congenita of the X chromosome 1 (DAX1) that inhibits SF-1-mediated steroidogenesis [40].

The Ad4 or SF-1 site has been identified in all steroid P450s based on sequence alignments, including at position −351/−343 (AGGTCC) of CYP11B2.Although this site binds strongly to SF-1, deletion studies suggest that it is not essential for basal or stimulus-induced expression of CYP11B2. In fact, co-expression of CYP11B2reporter gene constructs with SF-1 has a negative effect on gene transcription, making the regulation of CYP11B2different to the other steroidogenic genes, StAR, CYP11A, CYP11B1, and CYP 17that are all induced by SF-1. The effects of both NGFIB and NURRl on CYP11B2expression can be inhibited by SF-1 supporting a negative effect of SF-1 [33]. Thus, hCYP11B2expression is regulated quite differently from genes for other proteins involved in steroid biosynthesis including StAR, CYP11A, CYP11B1, and CYP17, which are all positively regulated by SF-1 [41]. AD5

Electrophoretic mobility shift assay (EMSA) analysis of the −129/−114 (Ad5) element (CTCCAGCCTTGACCTT) has shown that it binds several nuclear proteins, including SF-1 and another orphan nuclear receptor, chicken ovalbumin upstream promoter transcription factor (COUP-TF). On the bovine CYP 17and the mouse CYP21gene, COUP-TF and SF-1 bind competitively to a common site. Deletion of this site decreases basal activity by approximately 80% and also reduces the maximal response to Ca2+ and cAMP stimulation [42]. NBRE

The transcription factors nerve growth factor IB (NGFIB) and nuclear receptor-related 1 protein (NURRl) are members of the NGFIB family of orphan nuclear receptors that bind to a consensus sequence NGFI-B response element (NBRE) (AAAGGTCA). These factors can also bind to the Ad5 element as well as a novel NBRE-1 site at −766/−759. Both these transcription factors increase CYP11B2expression by angiotensin II or K+ stimulation. Mutation of the NBRE-1 site decreases basal expression as well as the response to angiotensin II and K+. Therefore, the CRE, Ad5, and NBRE-1 sites interact to regulate basal transcription as well as the response to each signaling pathway (cAMP or Ca2+) [33].


4. Genotypic variants and haplotypes in CYP11B2gene

Several polymorphisms have been identified in CYP11B2and are associated with enhanced CYP11B2transcription, increased aldosterone production, and the progression of many cardiovascular disorders (Figure 8). About 227 single-nucleotide polymorphisms (SNPs) have been detected in different population worldwide according to National Center for Biotechnology Information (NCBI) database ( [43]. However, only few SNPs are evaluated in different studies. The first and most extensively studied polymorphism is −344 C/T which exists in the 5′ promoter region of CYP11B2gene. It occupies the putative binding site for the transcription factor SF-1 which is responsible for the expression of several enzymes involved in steroid biosynthesis framework in the adrenal cortex. The two alternative bases at this position are thymine (T) and cytosine (C) [44]. CYP11B2−344C/T polymorphism is associated with increased aldosterone synthesis and secretion in serum [45] or urine [46] and increased aldosterone renin ratio [47, 48] with either C allele or T allele were suggested to be involved among different studies. The mechanisms that stand behind this association are conflicting. Functional studies showed that T allele binds to SF-1 with four folds lower affinity than the C allele. This results in stimulation of the expression of enzymes responsible for steroidogenesis leading to increased aldosterone synthase activity in C allele carriers [41]. However, in T allele carrier, the increased aldosterone production was explained by lower affinity for SF1 binding leading to the increased availability of this transcription factor in other parts of the gene with subsequent activation of the steroidogenic acute regulatory gene [45]. On the other hand, others suggest that this polymorphism exert its effect via a strong linkage disequilibrium with functional polymorphisms in CYP11B1, a substitution (T to C) in codon 75 and (G to A) in intron 6 that result in 11 β hydroxylase deficiency [49]. This results in sustained elevation of ACTH [50] with subsequent increases in the expression of a number of genes required for aldosterone synthesis including StAR, CYP11A, and CYP21leading to enhanced aldosterone synthesis [31, 50].

Figure 8.

Common CYP11B2polymorphisms associated with increased aldosterone production.

The second polymorphism is a gene intronic conversion (IC) whereby a fragment of the “wild-type (Wt)” intron 2 of CYP11B2is replaced by the corresponding intronic fragment of CYP11B1conversion (Conv). Due to the nature of this variation and difficulty in genotyping it, its frequency has not been reported in public databases. The −344 T/C and intron conversion polymorphisms are in tight linkage disequilibrium and three common haplotypes have been reported: T/Conv (38%), C/Wt (45%), and T/Wt (13%), where the first allele corresponds to the −344 polymorphism (T or C) and the second to the intron 2 conversion (Wt or Conv) [31].

Beside the previously described polymorphisms of CYP11B2, other interesting polymorphisms have been reported and associated with increased aldosterone production as missense mutation in exon 3, where a lysine is replaced by an arginine (K173R) and CYP11B2(T4991C) SNP in exon 7 [51]. However, the haplotype including −344T and K173 was associated with higher CYP11B2expression in adrenal tissue than the −344C and R173 haplotype [52]. Moreover, other polymorphisms have been studied as G5937C and A4550C and were associated with heart size [53].

4.1 CYP11B2genotypic variants and hypertension

Hypertension is a complex progressive cardiovascular disorder, not just a scale of threshold blood pressure values, with many causes that result in both functional and structural cardiac and vascular system abnormalities that damage the heart, kidneys, brain, vasculature, and other organs, and lead to premature morbidity and death [54]. Essential hypertension is a multifactorial disorder, predisposed by genetic and environmental factors [55]. Growing evidences suggest the potential role of genetic alteration affecting genes encoding the aldosterone synthesis pathway enzymes with associated enhanced aldosterone production resulting in progression to essential hypertension [56].

Several polymorphic variants of CYP11B2have been identified as potential genetic contributor in patients with essential hypertension with −344C/T was extensively studied among different ethnic groups, with conflicting results. Public databases reported that the T allele is more frequent than the C allele in highlanders compared with lowlanders Indian [57], African Americans and Japanese subjects [48], Caucasian [58], Tamil population [59], Chinese Han population [38], Taiwanese females [60], and recently in the Egyptian population [61]. C allele has been suggested to be associated with hypertension by Tsukada et al. [62], Kumar et al. [63], Ji et al. [64], Li et al. [65], and in the meta-analysis by Cheng et al. [66]. No association was detected in the Japanese population [67] and in the meta-analysis by Chen et al. [68]. These discrepancies reflect the influence of different genetic and environmental factors as well as the age and gender in geographically separated populations [61].

The CYP11B2gene intronic conversion (IC) was also described in a small study of essential hypertensive subjects; the conversion allele frequency was much lower in black subjects compared with white [69]. However, several studies proved the more frequent association of CYB11B2−344T/IC haplotype with hypertensive subjects than normotensives, especially those with a high aldosterone renin ratio (ARR) and increased aldosterone levels in plasma [45, 47], although this finding is not supported in all studies [67]. IC has also associated with a better therapeutic response to anti-hypertensive treatment [70].

On the other hand, CYP11B2(K173R) and CYP11B2(T4991C) polymorphisms were found to be associated with hypertension [51, 52]. A strong synergistic effect has existed among different genotypes of CYP11B2C−344T, IC, and K173R polymorphisms with the haplotype (−344T-Conv-K173) associated with a higher risk for essential hypertension progression [43]. Despite the use of several polymorphisms in CYP11B2,their causal relationship with hypertension and inappropriate aldosterone production remains unclear.

4.2 CYP11B2genotypic variants and atrial fibrillation

Atrial fibrillation (AF) is the most clinically prevalent type of cardiac arrhythmia which may be precipitated due to the presence of underlying heart disease such as valvular dysfunction, ventricular dysfunction, and hypertension. However, AF does not exist in some patients with one or more of these risk factors and presents in others without any risk factors. Accordingly, the genetic role had been emerged in the predisposition for AF. A positive family history of AF in at least one parent was suggested by a recent Framingham Heart study on 2243 participants to be associated with an 85% increased relative risk for AF [71].

Taking together this genetic role, two types of AF have been identified regarding the heredity characteristics as familial and non-familial AF. Recent studies have detected several candidate genes which were suggested to be associated with the familial AF type such as genes encoding for subunits of potassium or sodium channels, sarcolipin, connexin 40, endothelial nitric oxide synthase, interleukin 10, and RAAS [72].

Association of genetic variants of renin angiotensin aldosterone system (RAAS) system with non-familial AF was suggested by Tsai et al. [73] using a risk-factor matched design. CYP11B2−344C/T polymorphism was reported to be associated with the susceptibility of AF by Amir et al. [74] in a cohort of 196 patients with symptomatic systolic heart failure. They found that the −344 CC genotype to be a strong independent predictor for AF (adjusted OR 2.35, 95% CI 1.57–3.51, P= 0.03). Therefore, CYP11B2−344C/T polymorphism may predispose to AF in patients with HF. Another study by Lu et al. [75] on 359 of Han and Kazak population with non-valvular AF and 527 non-AF patients as a control reported that −344C/T polymorphism of CYP11B2was associated with AF risk as the frequencies of TT genotype, and co-dominant model (CC + TT genotype) in Han population and of TT genotype, and dominant model (CT + TT genotype) in Kasak population were significantly higher in AF group than in the control group. Furthermore, a meta-analysis by Li et al. [76] involving 2758 subjects from six distinct studies reported that CYP11B2T−344C gene polymorphism was significantly associated with AF in all genetic models; allelic (OR: 1.26, P= 0.0002), recessive (OR: 1.99, P= 0.003), dominant (OR: 0.903, P= 0.036), and homozygous (OR: 1.356, 95% CI: 1.130–1.628, P= 0.001), and additive (OR: 1.153, P= 1.0 × 10−10). On the other hand, no significant association was detected by Zhang et al. [77] between different genotype and alleles of −344 T/C polymorphism and lone AF patients.

The possible mechanisms for the association of CYP11B2polymorphism and AF are mainly related to increased aldosterone production. Aldosterone exerts its effect via direct and indirect ways. Indirect effect of aldosterone on the heart arise from its role on increasing blood volume, blood pressure, left ventricular pressure, left ventricular hypertrophy, left atrial pressure, and left atrial volume. However, aldosterone can directly act on the heart inducing cardiac hypertrophy and fibrosis [78, 79] via the proliferation and differentiation of myocardial cells, vascular smooth muscle cells, and fibroblasts, leading to a significant increase in collagen production. These effects lead to cardiac fibrosis and structural remodeling leading to heart rhythm disorders. Specifically, in the atrium, aldosterone may directly or indirectly cause atrial enlargement and fibrosis, leading to structural and electrical atrial remodeling resulting in atrial fibrillation. Based on these findings, aldosterone antagonists as angiotensin II receptor antagonists may be used clinically in the patients with AF to control and minimize the incidence and persistence of AF [80].

4.3 CYP11B2genotypic variants and coronary artery disease

Coronary artery disease (CAD) is a complex disorder comprised two major subsequent events: coronary atherosclerosis and myocardial infarction (MI). Despite the major progress in diagnosis of CAD, the pathogenesis and possible risk factors need further evaluation. The classical risk factors including positive family history, smoking, high body mass index, and disorders as hyperlipidemia, hypertension, and diabetes mellitus have been reported to be responsible for no more than 50% of total risk factors for CAD. Accordingly, genetic background seems also to participate in the predisposition for CAD [81].

Among the different polymorphisms described for CYP11B2gene, several studies have shown that the CYP11B2gene ˗344T>C polymorphism is associated with CAD in different ethnic groups with controversial results. Previous study on 201 CAD patients and 201 controls form Italian population have detected that CYP11B2polymorphism and CC genotype were associated with CAD risk in crude analysis with borderline significance which is lost by stratification to the confounding factors as smoking and family history [82]. A meta-analysis suggested that the −344T>C polymorphism in the CYP11B2gene might be associated with susceptibility to CAD in Caucasians and Asians [83]. A study on 609 Taiwanese male and female subjects who were unrelated and received coronary catheterization found that the C/C allele occurred more frequently in females who had CAD, and that it was associated with higher left ventricular mass (LVM) and left ventricular end diastolic diameter (LVEDD) [84]. Sharma et al. [85] also reported the association of the CYP11B2−344C>T polymorphism with the size of atherosclerotic plaque in the carotid artery. Neal et al. [86] suggested that −344C/T polymorphism is a cardiovascular risk factor due to its association with LV hypertrophy and decreased baroreflex sensitivity which predict the morbidity and mortality rates of MI. Others failed to find any significant association of CYP11B2with CAD in different populations as in an Indian population and other populations [87, 88, 89].

The underlying mechanism by which the CYP11B2˗344T>C polymorphism can increase the risk for CAD remains unclear. However, it is related to its effect on increasing expression of CYP11B2, thereby increasing aldosterone secretion [83]. Also, the influence of gene-environment interaction has been involved as an etiological factor for CAD risk. Growing evidence has suggested the interaction between ˗344T>C polymorphism and positive smoking for enhanced CAD risk [90]. Also, Hautanen et al. [91] detected that smoking and dyslipidemia are associated risk factors for non-fatal MI in males who were carriers for CYP11B2−344C/T allele.

4.4 CYP11B2genotypic variants and hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is a clinical cardiac dysfunction characterized mainly by hypertrophy of left ventricle. HCM is an autosomal dominant disorder and its diagnosis needs to exclude other cardiac or systemic causes of increased ventricular wall thickening. HCM comprises different histological features as cardiomyocyte hypertrophy, myofibrillar disarray, and fibrosis. Several factors are involved in the pathogenesis of HCM, with the genetic element has an upper hand. Mutations and polymorphisms in genes encoding the sarcomere proteins and renin-angiotensin-aldosterone system (RAAS) seem to be related to the predisposition for left ventricular hypertrophy (LVH) and HCM [92].

Evidences suggested that aldosterone seems to play a major role in the progression of LVH and HCM as it is produced locally in the heart and CYP11B2mRNA levels show sevenfold increase in the cardiac tissue of HCM patients when compared normal cardiac tissue [93]. It exerts its action via stimulation of mineralocorticoid receptor resulting in enhancement of myocardial cell hypertrophy, progressive myocardial fibrosis leading to ventricular and septal remodeling, and hypertrophy, resulting in elevated ventricular mass observed in HCM patients [94, 95]. Therefore, genetic variations involving CYP11B2gene might influence the structure and function of the left ventricle via increasing aldosterone secretion [93].

Several polymorphisms in the CYP11B2had been described in the HCM with −344C>T and intron 2 conversion have significant associations with left ventricular size, mass, and function in different population studies. However, the −344C>T promoter polymorphism is a much better predictor of left ventricular size than is the intron 2 gene conversion [96]. The −344C>T polymorphism have proved to be associated with the risk for HCM progression in many previous studies [93, 94, 97, 98, 99], whereas no association has suggested by other studies [100, 101].This controversy extents to the risk allele, which may be the −344C in some studies [96, 98, 99, 100, 102, 103] or −344T in another study [97]. Moreover, the risk allele for increased ventricular size and thickness differs regarding gender as with a study by Chai et al., [97] in which the T allele carrier is associated with a significantly higher intra-ventricular septum thickness in males, whereas in females, CC genotype carriers had a higher risk for increased intra-ventricular mass thickness, left ventricular mass index, and Wigle score.

4.5 CYP11B2genotypic variants and heart failure

Heart failure (HF) is a cardiac disorder characterized by cardiac remodeling with subsequent cardiac dysfunction [104]. It is a multifactorial disease, which is precipitated due to underlying cardiac disorders as hypertension, CAD, valvular dysfunction, arrhythmia, and cardiomyopathy. Integrated neuronal and hormonal elements are involved in the pathogenesis of HF including activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system, and other mediators as endothelin, vascular endothelial growth factor, and inflammatory cytokines. Based on the previously described neurohormonal factors, therapeutic approaches for HF have developed to block these factors including angiotensin-converting enzyme inhibitors (ACEI), and aldosterone antagonists [105]. Several risk and prognostic factors have influenced the progression of chronic congestive heart failure (CHF) including age, New York Heart Association (NYHA) class, renal function, and comorbidities such as atrial fibrillation, diabetes mellitus, and ischemic heart disease [106]. However, genetic elements seem to affect the risk, severity, and therapeutic response of HF [107]. CYP11B2polymorphisms specifically −344C/T is among these genetic factors and has been associated with the susceptibility, therapeutic response, or prognosis of HF.

A study by McNamara et al. [108] was performed on a total of 354 subjects from A-HeFT (African American Heart Failure Trial). They detected a higher frequency of −344 TT genotypes carriers (61%) than CC genotypes carriers (6.2%) in African Americans. Also, the −344 C allele was associated with significantly poorer HF hospitalization-free survival and a higher rate of death. Moreover, the therapeutic influence of nitric oxide donor (isosorbide dinitrate and hydralazine) was augmented in the presence of the TT genotype.

Another study by Feola et al. [109] on 175 patients from the European continental ancestry congestive heart failure (CHF) population and revealed that no significant differences between −344 CC and −344 TT genotypes carriers regarding cardiac output, end-systolic or diastolic left ventricle diameter, left ventricular ejection fraction (LVEF), and pro-natriuretic peptide (BNP). Also, −344 C allele carriers have a higher degree of disability (Barthel Index), NYHA class, and a lower cardiac index. Moreover, the two groups showed a similar clinical outcomes either death or re-hospitalization after 4 years follow up period.

In 107 Black South African patients with dilated cardiomyopathy in functional class II–III, Tiago et al. [110] detected that the −344C allele was associated with improvement of LVEF after traditional therapy despite it is not related to the baseline LVEF as well as left ventricular dimension. Also, the allele distribution has proven to be different among races as the C allele was significantly more frequent in non-African-American HF patients if compared with African-American patients and associated only in the African-American with a lower end-systolic left ventricular diameter at 1 year follow-up [111]. Moreover, the association of −344C allele was confirmed as a risk factor for the progression of AF in a cohort of 194 African-American HF patients [112].


5. Conclusions

CYP11B2gene polymorphism is associated with increased cardiovascular risk via enhancing aldosterone synthesis and production which acts either systemically or locally on the heart. There is a large number of polymorphisms has been identified for CYP11B2. Among them, 344C/T polymorphism was extensively studied in different ethnic groups and has proved to be associated either solely or synergistic with other CYP11B2polymorphisms in the risk for progression and susceptibility of several cardiovascular disorders as hypertension, AF, CAD, cardiomyopathy, and HF. Also, CYP11B2polymorphisms were confirmed as a predictor for survival and therapeutic response in some cardiovascular disorders as hypertension and HF. Moreover, gene-environment interactions of CYP11B2were suggested in several studies but still need to be confirmed.


First of all thanks to gracious ALLAH who guided me to the frank clear way. Second, I dedicate this work to my parents and my dear professor Murad Ahmad Murad for their encouragement and sustained support. And finally, I am grateful to my lovely niece, Marium.


  1. 1. Davies E, MacKenzie SM. Extra-adrenal production of corticosteroids. Clinical and Experimental Pharmacology & Physiology. 2003;30(7):437-445
  2. 2. Stocco DM. StAR protein and the regulation of steroid hormone biosynthesis. Annual Review of Physiology. 2001;63:193-213
  3. 3. Lieberman S, Lin YY. Reflections on sterol sidechain cleavage process catalyzed by cytochrome P450(scc). The Journal of Steroid Biochemistry and Molecular Biology. 2001;78(1):1-14
  4. 4. Connell JM, Davies E. The new biology of aldosterone. The Journal of Endocrinology. 2005;186(1):1-20
  5. 5. Rogerson FM, Brennan FE, Fuller PJ. Mineralocorticoid receptor binding, structure and function. Molecular and Cellular Endocrinology. 2004;217(1-2):203-212
  6. 6. Naray-Fejes-Toth A, Helms MN, Stokes JB, Fejes-Toth G. Regulation of sodium transport in mammalian collecting duct cells by aldosterone-induced kinase, SGK1: Structure/function studies. Molecular and Cellular Endocrinology. 2004;217(1-2):197-202
  7. 7. Snyder PM, Olson DR, Thomas BC. Serum and glucocorticoid-regulated kinase modulates Nedd4-2-mediated inhibition of the epithelial Na+ channel. The Journal of Biological Chemistry. 2002;277(1):5-8
  8. 8. Bhalla V, Soundararajan R, Pao AC, Li H, Pearce D. Disinhibitory pathways for control of sodium transport: Regulation of ENaC by SGK1 and GILZ. American Journal of Physiology. Renal Physiology. 2006;291(4):F714-F721
  9. 9. Chatterjee VK, Beck-Peccoz P. Hormone-nuclear receptor interactions in health and disease: Thyroid hormone resistance. Baillière’s Clinical Endocrinology and Metabolism. 1994;8(2):267-283
  10. 10. Losel R, Schultz A, Wehling M. A quick glance at rapid aldosterone action. Molecular and Cellular Endocrinology. 2004;217(1-2):137-141
  11. 11. Pearce D, Bhargava A, Cole TJ. Aldosterone: Its receptor, target genes, and actions. Vitamins and Hormones. 2003;66:29-76
  12. 12. Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE. Origin of aldosterone in the rat heart. Endocrinology. 2004;145(11):4796-4802
  13. 13. Horisberger JD. Amiloride-sensitive Na channels. Current Opinion in Cell Biology. 1998;10(4):443-449
  14. 14. Kim GH, Masilamani S, Turner R, Mitchell C, Wade JB, Knepper MA. The thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(24):14552-14557
  15. 15. Young MJ, Moussa L, Dilley R, Funder JW. Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: Effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology. 2003;144(3):1121-1125
  16. 16. Sheppard KE, Autelitano DJ. 11Beta-hydroxysteroid dehydrogenase 1 transforms 11-dehydrocorticosterone into transcriptionally active glucocorticoid in neonatal rat heart. Endocrinology. 2002;143(1):198-204
  17. 17. Tomaschitz A, Pilz S, Ritz E, Obermayer-Pietsch B, Pieber TR. Aldosterone and arterial hypertension. Nature Reviews Endocrinology. 2010;6(2):83-93
  18. 18. Young M, Funder JW. Aldosterone and the heart. Trends in Endocrinology and Metabolism. 2000;11(6):224-226
  19. 19. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocrine Reviews. 2004;25(6):947-970
  20. 20. White PC, Curnow KM, Pascoe L. Disorders of steroid 11 beta-hydroxylase isozymes. Endocrine Reviews. 1994;15(4):421-438
  21. 21. Gomez-Sanchez CE, Gomez-Sanchez EP. Immunohistochemistry of the adrenal in primary aldosteronism. Current Opinion in Endocrinology, Diabetes, and Obesity. 2016;23(3):242-248
  22. 22. Miller WL, Bose HS. Early steps in steroidogenesis: Intracellular cholesterol trafficking. Journal of Lipid Research. 2011;52(12):2111-2135
  23. 23. Dores RM, Londraville RL, Prokop J, Davis P, Dewey N, Lesinski N. Molecular evolution of GPCRs: Melanocortin/melanocortin receptors. Journal of Molecular Endocrinology. 2014;52(3):T29-T42
  24. 24. El Ghorayeb N, Bourdeau I, Lacroix A. Role of ACTH and other hormones in the regulation of aldosterone production in primary aldosteronism. Frontiers in Endocrinology. 2016;7:72
  25. 25. Evans JF, Fernando A, Ragolia L. Functional melanocortin-2 receptors are expressed by mouse aorta-derived mesenchymal progenitor cells. Molecular and Cellular Endocrinology. 2012;355(1):60-70
  26. 26. Bassett MH, White PC, Rainey WE. The regulation of aldosterone synthase expression. Molecular and Cellular Endocrinology. 2004;217(1-2):67-74
  27. 27. Shen Y, Xu L, Foster DA. Role for phospholipase D in receptor-mediated endocytosis. Molecular and Cellular Biology. 2001;21(2):595-602
  28. 28. Condon JC, Pezzi V, Drummond BM, Yin S, Rainey WE. Calmodulin-dependent kinase I regulates adrenal cell expression of aldosterone synthase. Endocrinology. 2002;143(9):3651-3657
  29. 29. Spat A, Hunyady L, Szanda G. Signaling interactions in the adrenal cortex. Frontiers in Endocrinology. 2016;7:17
  30. 30. Spat A, Hunyady L. Control of aldosterone secretion: A model for convergence in cellular signaling pathways. Physiological Reviews. 2004;84(2):489-539
  31. 31. Freel EM, Connell JM. Mechanisms of hypertension: The expanding role of aldosterone. Journal of the American Society of Nephrology. 2004;15(8):1993-2001
  32. 32. Gomez-Sanchez CE, Oki K. Minireview: Potassium channels and aldosterone dysregulation: Is primary aldosteronism a potassium channelopathy? Endocrinology. 2014;155(1):47-55
  33. 33. Bassett MH, Suzuki T, Sasano H, White PC, Rainey WE. The orphan nuclear receptors NURR1 and NGFIB regulate adrenal aldosterone production. Molecular Endocrinology. 2004;18(2):279-290
  34. 34. Thiel G, Al Sarraj J, Vinson C, Stefano L, Bach K. Role of basic region leucine zipper transcription factors cyclic AMP response element binding protein (CREB), CREB2, activating transcription factor 2 and CAAT/enhancer binding protein alpha in cyclic AMP response element-mediated transcription. Journal of Neurochemistry. 2005;92(2):321-336
  35. 35. Naqvi S, Martin KJ, Arthur JS. CREB phosphorylation at Ser133 regulates transcription via distinct mechanisms downstream of cAMP and MAPK signalling. The Biochemical Journal. 2014;458(3):469-479
  36. 36. Johannessen M, Delghandi MP, Seternes OM, Johansen B, Moens U. Synergistic activation of CREB-mediated transcription by forskolin and phorbol ester requires PKC and depends on the glutamine-rich Q2 transactivation domain. Cellular Signalling. 2004;16(10):1187-1199
  37. 37. Cheng LC, Pai TW, Li LA. Regulation of humanCYP11B1andCYP11B2promoters by transposable elements and conserved cis elements. Steroids. 2012;77(1-2):100-109
  38. 38. Li W, Liu C. The −344C/T polymorphism in theCYP11B2gene is associated with essential hypertension in the Chinese. Journal of the Renin-Angiotensin-Aldosterone System. 2014;15(2):150-155
  39. 39. Gardiner JR, Shima Y, Morohashi K, Swain A. SF-1 expression during adrenal development and tumourigenesis. Molecular and Cellular Endocrinology. 2012;351(1):12-18
  40. 40. Suntharalingham JP, Buonocore F, Duncan AJ, Achermann JC. DAX-1 (NR0B1) and steroidogenic factor-1 (SF-1, NR5A1) in human disease. Best Practice & Research: Clinical Endocrinology & Metabolism. 2015;29(4):607-619
  41. 41. Bassett MH, Zhang Y, Clyne C, White PC, Rainey WE. Differential regulation of aldosterone synthase and 11beta-hydroxylase transcription by steroidogenic factor-1. Journal of Molecular Endocrinology. 2002;28(2):125-135
  42. 42. Shibata H, Ikeda Y, Mukai T, Morohashi K, Kurihara I, Ando T, et al. Expression profiles of COUP-TF, DAX-1, and SF-1 in the human adrenal gland and adrenocortical tumors: Possible implications in steroidogenesis. Molecular Genetics and Metabolism. 2001;74(1-2):206-216
  43. 43. Vamsi UM, Swapna N, Padma G, Vishnupriya S, Padma T. Haplotype association and synergistic effect of human aldosterone synthase (CYP11B2) gene polymorphisms causing susceptibility to essential hypertension in Indian patients. Clinical and Experimental Hypertension. 2016;38(8):659-665
  44. 44. White PC, Rainey WE. Editorial: Polymorphisms inCYP11Bgenes and 11-hydroxylase activity. The Journal of Clinical Endocrinology and Metabolism. 2005;90(2):1252-1255
  45. 45. Nicod J, Bruhin D, Auer L, Vogt B, Frey FJ, Ferrari P. A biallelic gene polymorphism ofCYP11B2predicts increased aldosterone to renin ratio in selected hypertensive patients. The Journal of Clinical Endocrinology and Metabolism. 2003;88(6):2495-2500
  46. 46. Staessen JA, Wang JG, Brand E, Barlassina C, Birkenhager WH, Herrmann SM, et al. Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. Journal of Hypertension. 2001;19(8):1349-1358
  47. 47. Lim PO, Macdonald TM, Holloway C, Friel E, Anderson NH, Dow E, et al. Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio. The Journal of Clinical Endocrinology and Metabolism. 2002;87(9):4398-4402
  48. 48. Sookoian S, Gianotti TF, Gonzalez CD, Pirola CJ. Association of the C-344T aldosterone synthase gene variant with essential hypertension: A meta-analysis. Journal of Hypertension. 2007;25(1):5-13
  49. 49. Ganapathipillai S, Laval G, Hoffmann IS, Castejon AM, Nicod J, Dick B, et al.CYP11B2-CYP11B1haplotypes associated with decreased 11 beta-hydroxylase activity. The Journal of Clinical Endocrinology and Metabolism. 2005;90(2):1220-1225
  50. 50. Connell JM, Fraser R, MacKenzie S, Davies E. Is altered adrenal steroid biosynthesis a key intermediate phenotype in hypertension? Hypertension. 2003;41(5):993-999
  51. 51. Keavney B, Mayosi B, Gaukrodger N, Imrie H, Baker M, Fraser R, et al. Genetic variation at the locus encompassing 11-beta hydroxylase and aldosterone synthase accounts for heritability in cortisol precursor (11-deoxycortisol) urinary metabolite excretion. The Journal of Clinical Endocrinology and Metabolism. 2005;90(2):1072-1077
  52. 52. Tanahashi H, Mune T, Takahashi Y, Isaji M, Suwa T, Morita H, et al. Association of Lys173Arg polymorphism withCYP11B2expression in normal adrenal glands and aldosterone-producing adenomas. The Journal of Clinical Endocrinology and Metabolism. 2005;90(11):6226-6231
  53. 53. Mayosi BM, Keavney B, Watkins H, Farrall M. Measured haplotype analysis of the aldosterone synthase gene and heart size. European Journal of Human Genetics. 2003;11(5):395-401
  54. 54. Giles TD, Materson BJ, Cohn JN, Kostis JB. Definition and classification of hypertension: An update. Journal of Clinical Hypertension. 2009;11(11):611-614
  55. 55. Sarkar T, Singh NP. Epidemiology and genetics of hypertension. The Journal of the Association of Physicians of India. 2015;63(9):61-98
  56. 56. Padmanabhan S, Caulfield M, Dominiczak AF. Genetic and molecular aspects of hypertension. Circulation Research. 2015;116(6):937-959
  57. 57. Rajput C, Arif E, Vibhuti A, Stobdan T, Khan AP, Norboo T, et al. Predominance of interaction among wild-type alleles ofCYP11B2in Himalayan natives associates with high-altitude adaptation. Biochemical and Biophysical Research Communications. 2006;348(2):735-740
  58. 58. Casiglia E, Tikhonoff V, Mazza A, Rynkiewicz A, Limon J, Caffi S, et al. C-344T polymorphism of the aldosterone synthase gene and blood pressure in the elderly: A population-based study. Journal of Hypertension. 2005;23(11):1991-1996
  59. 59. Rajan S, Ramu P, Shewade DG, Adithan C. Promotor gene polymorphism ofCYP11B2(344C>T) of healthy volunteer of south Indian tamilian population. Indian Journal of Biotechnology. 2009;8:358-362
  60. 60. Sia SK, Chiou HL, Chen SC, Tsai CF, Yang SF, Ueng KC. Distribution and phenotypic expression of mineralocorticoid receptor andCYP11B2T-344C polymorphisms in a Taiwanese hypertensive population. Molecular Biology Reports. 2013;40(5):3705-3711
  61. 61. Abdel Ghafar MT. Association of aldosterone synthaseCYP11B2(−344C/T) gene polymorphism with essential hypertension and left ventricular hypertrophy in the Egyptian population. Clinical and Experimental Hypertension. 2019;41(8):779-786
  62. 62. Tsukada K, Ishimitsu T, Teranishi M, Saitoh M, Yoshii M, Inada H, et al. Positive association ofCYP11B2gene polymorphism with genetic predisposition to essential hypertension. Journal of Human Hypertension. 2002;16(11):789-793
  63. 63. Kumar NN, Benjafield AV, Lin RC, Wang WY, Stowasser M, Morris BJ. Haplotype analysis of aldosterone synthase gene (CYP11B2) polymorphisms shows association with essential hypertension. Journal of Hypertension. 2003;21(7):1331-1337
  64. 64. Ji X, Qi H, Li DB, Liu RK, Zheng Y, Chen HL, et al. Associations between human aldosterone synthaseCYP11B2(−344T/C) gene polymorphism and antihypertensive response to valsartan in Chinese patients with essential hypertension. International Journal of Clinical and Experimental Medicine. 2015;8(1):1173-1177
  65. 65. Li X, Xie P, He J, Cai H, Yang R, Zhang Q , et al.CYP11B2gene polymorphism and essential hypertension among Tibetan, Dongxiang and Han populations from northwest of China. Clinical and Experimental Hypertension. 2016;38(4):375-380
  66. 66. Cheng X, Xu G. Association between aldosterone synthaseCYP11B2polymorphism and essential hypertension in Chinese: A meta-analysis. Kidney & Blood Pressure Research. 2009;32(2):128-140
  67. 67. Tsujita Y, Iwai N, Katsuya T, Higaki J, Ogihara T, Tamaki S, et al. Lack of association between genetic polymorphism ofCYP11B2and hypertension in Japanese: The Suita study. Hypertension Research. 2001;24(2):105-109
  68. 68. Chen JF, Jing J, Tan H, Song MB, Yu SY, Huang L. Lack of association ofCYP11B2-344C/T polymorphism with essential hypertension: A meta-analysis. International Journal of Clinical and Experimental Medicine. 2015;8(6):9162-9167
  69. 69. Zhu H, Sagnella GA, Dong Y, Miller MA, Onipinla A, Markandu ND, et al. Contrasting associations between aldosterone synthase gene polymorphisms and essential hypertension in blacks and in whites. Journal of Hypertension. 2003;21(1):87-95
  70. 70. Yu H, Lin S, Zhang Y, Liu G. Intron-2 conversion polymorphism of the aldosterone synthase gene and the antihypertensive response to angiotensin-converting enzyme inhibitors. Journal of Hypertension. 2008;26(2):251-256
  71. 71. Fox CS, Parise H, D'Agostino RB Sr, Lloyd-Jones DM, Vasan RS, Wang TJ, et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA. 2004;291(23):2851-2855
  72. 72. Tsai CT, Lai LP, Hwang JJ, Lin JL, Chiang FT. Molecular genetics of atrial fibrillation. Journal of the American College of Cardiology. 2008;52(4):241-250
  73. 73. Tsai CT, Lai LP, Lin JL, Chiang FT, Hwang JJ, Ritchie MD, et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation. 2004;109(13):1640-1646
  74. 74. Amir O, Amir RE, Paz H, Mor R, Sagiv M, Lewis BS. Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure. The American Journal of Cardiology. 2008;102(3):326-329
  75. 75. Lu WH, Bayike M, Liu JW, Wang S, Xie X, Yang YC, et al. Association between aldosterone synthase (CYP11B2) −344C/T polymorphism and atrial fibrillation among Han and Kazak residents of the Xinjiang region. International Journal of Clinical and Experimental Medicine. 2015;8(4):5513-5519
  76. 76. Li YY, Zhou CW, Xu J, Qian Y, Wang B.CYP11B2T-344C gene polymorphism and atrial fibrillation: A meta-analysis of 2,758 subjects. PLoS One. 2012;7(11):e50910
  77. 77. Zhang XL, Wu LQ , Liu X, Yang YQ , Tan HW, Wang XH, et al. Association of angiotensin-converting enzyme gene I/D andCYP11B2gene −344T/C polymorphisms with lone atrial fibrillation and its recurrence after catheter ablation. Experimental and Therapeutic Medicine. 2012;4(4):741-747
  78. 78. Niu W, Qi Y, Hou S, Zhai X, Zhou W, Qiu C. Haplotype-based association of the renin-angiotensin-aldosterone system genes polymorphisms with essential hypertension among Han Chinese: The Fangshan study. Journal of Hypertension. 2009;27(7):1384-1391
  79. 79. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? European Heart Journal. 2006;27(2):136-149
  80. 80. Dixen U, Ravn L, Soeby-Rasmussen C, Paulsen AW, Parner J, Frandsen E, et al. Raised plasma aldosterone and natriuretic peptides in atrial fibrillation. Cardiology. 2007;108(1):35-39
  81. 81. Sekuri C, Cam FS, Ercan E, Tengiz I, Sagcan A, Eser E, et al. Renin-angiotensin system gene polymorphisms and premature coronary heart disease. Journal of the Renin-Angiotensin-Aldosterone System. 2005;6(1):38-42
  82. 82. Franco E, Palumbo L, Crobu F, Anselmino M, Frea S, Matullo G, et al. Renin-angiotensin-aldosterone system polymorphisms: A role or a hole in occurrence and long-term prognosis of acute myocardial infarction at young age. BMC Medical Genetics. 2007;8:27
  83. 83. Liu Y, Liu HL, Han W, Yu SJ, Zhang J. Association between theCYP11B2gene −344T>C polymorphism and coronary artery disease: A meta-analysis. Genetics and Molecular Research. 2015;14(2):3121-3128
  84. 84. Chou CH, Ueng KC, Yang SF, Wu CH, Wang PH. Relationship of genetic polymorphisms of aldosterone synthase gene cytochrome P450 11B2 and mineralocorticoid receptors with coronary artery disease in Taiwan. International Journal of Medical Sciences. 2016;13(2):117-123
  85. 85. Sharma R, Katz J. Preliminary studies on human aldosterone synthase (CYP11B2) gene polymorphism, matrix metalloprotease-9, apoptosis, and carotid atherosclerosis plaque size by proton magnetic resonance imaging. Journal of the Renin-Angiotensin-Aldosterone System. 2010;11(3):198-204
  86. 86. Padmanabhan N, Padmanabhan S, Connell JM. Genetic basis of cardiovascular disease--the renin-angiotensin-aldosterone system as a paradigm. Journal of the Renin-Angiotensin-Aldosterone System. 2000;1(4):316-324
  87. 87. Borzyszkowska J, Stanislawska-Sachadyn A, Wirtwein M, Sobiczewski W, Ciecwierz D, Targonski R, et al. Angiotensin converting enzyme gene polymorphism is associated with severity of coronary artery disease in men with high total cholesterol levels. Journal of Applied Genetics. 2012;53(2):175-182
  88. 88. Mishra A, Srivastava A, Mittal T, Garg N, Mittal B. Impact of renin-angiotensin-aldosterone system gene polymorphisms on left ventricular dysfunction in coronary artery disease patients. Disease Markers. 2012;32(1):33-41
  89. 89. Sarzani R, Salvi F, Dessi-Fulgheri P, Catalini R, Mazzara D, Cola G, et al. Aldosterone synthase alleles and cardiovascular phenotype in young adults. Journal of Human Hypertension. 2003;17(12):859-864
  90. 90. Jia EZ, Xu ZX, Guo CY, Li L, Gu Y, Zhu TB, et al. Renin-angiotensin-aldosterone system gene polymorphisms and coronary artery disease: Detection of gene-gene and gene-environment interactions. Cellular Physiology and Biochemistry. 2012;29(3-4):443-452
  91. 91. Hautanen A, Toivanen P, Manttari M, Tenkanen L, Kupari M, Manninen V, et al. Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. Circulation. 1999;100(22):2213-2218
  92. 92. Ommen SR, Nishimura RA. Hypertrophic cardiomyopathy. Current Problems in Cardiology. 2004;29(5):239-291
  93. 93. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation. 2004;109(10):1284-1291
  94. 94. Bureik M, Hubel K, Dragan CA, Scher J, Becker H, Lenz N, et al. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension. Molecular and Cellular Endocrinology. 2004;217(1-2):249-254
  95. 95. Yoshida Y, Morimoto T, Takaya T, Kawamura T, Sunagawa Y, Wada H, et al. Aldosterone signaling associates with p300/GATA4 transcriptional pathway during the hypertrophic response of cardiomyocytes. Circulation Journal. 2010;74(1):156-162
  96. 96. Kupari M, Hautanen A, Lankinen L, Koskinen P, Virolainen J, Nikkila H, et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation. 1998;97(6):569-575
  97. 97. Chai W, Hoedemaekers Y, van Schaik RH, van Fessem M, Garrelds IM, Saris JJ, et al. Cardiac aldosterone in subjects with hypertrophic cardiomyopathy. Journal of the Renin-Angiotensin-Aldosterone System. 2006;7(4):225-230
  98. 98. Ortlepp JR, Vosberg HP, Reith S, Ohme F, Mahon NG, Schroder D, et al. Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: A study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene. Heart. 2002;87(3):270-275
  99. 99. Perkins MJ, Van Driest SL,Ellsworth EG, Will ML, Gersh BJ, Ommen SR, et al. Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. European Heart Journal. 2005;26(22):2457-2462
  100. 100. Ortlepp JR, Breithardt O, Ohme F, Hanrath P, Hoffmann R. Lack of association among five genetic polymorphisms of the renin-angiotensin system and cardiac hypertrophy in patients with aortic stenosis. American Heart Journal. 2001;141(4):671-676
  101. 101. Schunkert H, Hengstenberg C, Holmer SR, Broeckel U, Luchner A, Muscholl MW, et al. Lack of association between a polymorphism of the aldosterone synthase gene and left ventricular structure. Circulation. 1999;99(17):2255-2260
  102. 102. Bleumink GS, Schut AF, Sturkenboom MC, Deckers JW, van Duijn CM, Stricker BH. Genetic polymorphisms and heart failure. Genetics in Medicine. 2004;6(6):465-474
  103. 103. Kaufman BD, Auerbach S, Reddy S, Manlhiot C, Deng L, Prakash A, et al. RAAS gene polymorphisms influence progression of pediatric hypertrophic cardiomyopathy. Human Genetics. 2007;122(5):515-523
  104. 104. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002;288(17):2144-2150
  105. 105. McMurray JJ, Pfeffer MA. Heart failure. Lancet. 2005;365(9474):1877-1889
  106. 106. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. European Heart Journal. 2005;26(11):1115-1140
  107. 107. Muthumala A, Drenos F, Elliott PM, Humphries SE. Role of beta adrenergic receptor polymorphisms in heart failure: Systematic review and meta-analysis. European Journal of Heart Failure. 2008;10(1):3-13
  108. 108. McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Janosko K, Taylor AL, et al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: Results from the A-HeFT Trial. Journal of the American College of Cardiology. 2006;48(6):1277-1282
  109. 109. Feola M, Monteverde M, Vivenza D, Testa M, Leto L, Astesana V, et al. Prognostic value of different allelic polymorphism of aldosterone synthase receptor in a congestive heart failure European continental ancestry population. Archives of Medical Research. 2017;48(2):156-161
  110. 110. Tiago AD, Badenhorst D, Skudicky D, Woodiwiss AJ, Candy GP, Brooksbank R, et al. An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy. Cardiovascular Research. 2002;54(3):584-589
  111. 111. Biolo A, Chao T, Duhaney TA, Kotlyar E, Allensworth-Davies D, Loscalzo J, et al. Usefulness of the aldosterone synthase gene polymorphism C−344-T to predict cardiac remodeling in African-Americans versus non-African-Americans with chronic systolic heart failure. The American Journal of Cardiology. 2007;100(2):285-290
  112. 112. Bress A, Han J, Patel SR, Desai AA, Mansour I, Groo V, et al. Association of aldosterone synthase polymorphism (CYP11B2−344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure. PLoS One. 2013;8(7):e71268

Written By

Muhammad Tarek Abdel Ghafar

Submitted: March 15th, 2019 Reviewed: August 12th, 2019 Published: October 9th, 2019